Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Beyond oil: The crucial exports blocked by Hormuz closure - 2UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- 3Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- 4Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- 5Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
- Vote in favor of your Favored sort of footwear
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes
- Instructions to Really Oversee Unsold SUVs in the Auto Business
- Vote in favor of Your #1 BWM Vehicles
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- Governors Ball 2026: Lorde, A$AP Rocky and Stray Kids set to headline
- NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
